Rezultati - Geneviève Legault

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    <i>BRAF</i>Alterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549

    <i>BRAF</i>Alterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549 od Alex Y. Lin, Fausto J. Rodríguez, Matthias A. Karajannis, Susan Williams, Geneviève Legault, David Zagzag, Peter C. Burger, Jeffrey C. Allen, Charles G. Eberhart, Eli E. Bar

    Izdano 2011
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas

    Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas od Matthias A. Karajannis, Geneviève Legault, Mari Hagiwara, Marc Ballas, Krysten Brown, Annette O. Nusbaum, Tsivia Hochman, Judith D. Goldberg, Kevin M. Koch, John G. Golfinos, J. Thomas Roland, Jeffrey C. Allen

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas

    Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas od Matthias A. Karajannis, Geneviève Legault, Mari Hagiwara, Filippo G. Giancotti, Alexander S. Filatov, Anna Derman, Tsivia Hochman, Judith D. Goldberg, Emilio Vega-Gonzales, Jeffrey H. Wisoff, John G. Golfinos, Amanda Merkelson, J. Thomas Roland, Jeffrey C. Allen

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

    A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01 od Sébastien Perreault, Valérie Larouche, Uri Tabori, Cynthia Hawkin, Sarah Lippé, Benjamin Ellezam, Jean‐Claude Décarie, Yves Théorêt, Marie‐Élaine Métras, Serge Sultan, Édith Cantin, Marie-Ève Routhier, Maxime Caru, Geneviève Legault, Éric Bouffet, Lucie Lafay‐Cousin, Juliette Hukin, Craig Erker, Nada Jabado

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas

    Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas od Matthias A. Karajannis, Geneviève Legault, Michael J. Fisher, Sarah Sarvis Milla, Kenneth J. Cohen, Jeffrey H. Wisoff, D. H. Harter, Judith D. Goldberg, T. Hochman, Amanda Merkelson, Michael Bloom, A. J. Sievert, Adam Resnick, Girish Dhall, David Jones, Andrey Korshunov, Stefan M. Pfister, Charles G. Eberhart, David Zagzag, Jeffrey C. Allen

    Izdano 2014
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: